| Amgen Inc (AMGN) | |||
|---|---|---|---|
| 264.07 -1.57 (-0.59%) | 04-17 16:00 | ||
| Open: | 267.54 | Pre. Close: | 265.64 |
| High: | 268.775 | Low: | 263.385 |
| Volume: | 2,170,191 | Market Cap: | 141,520(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 325.81  One year: 337.05 |
| Support: | Support1: 263.39 Support2: 219.14 |
| Resistance: | Resistance1: 278.95 Resistance2: 288.57 |
| Pivot: | 272.06 |
| Moving Averages: | MA(5): 266.50 MA(20): 273.48 MA(100): 285.00  MA(250): 262.56 |
| MACD: | MACD(12,26): -4.07 Signal(12,26,9): -3.44 |
| %K %D: | %K(14,3): 4.97 %D(3): 8.50 |
| RSI: | RSI(14): 35.40 |
| 52-Week: | High: 329.72 Low: 211.71 Change(%): 7.3 |
| Average Vol(K): | 3-Month: 2945 10-Days: 2049 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 269.111 - 270.419 | 270.419 - 271.708 |
| Low: | 259.518 - 261.167 | 261.167 - 262.792 |
| Close: | 261.025 - 263.632 | 263.632 - 266.201 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMGN ] has closed above bottom band by 21.5%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 535.92 |
| Shares Float (M) | 534.35 |
| % Held by Insiders | 0.25 |
| % Held by Institutions | 80.74 |
| Shares Short (K) | 10470 |
| Shares Short Prior Month (K) | 11020 |
| Stock Financials | |
|---|---|
| EPS | 12.480 |
| Book Value (p.s.) | 11.640 |
| Profit Margin | 23.83 |
| Operating Margin | 8.15 |
| Return on Assets (ttm) | 6.3 |
| Return on Equity (ttm) | 135.8 |
| Qtrly Rev. Growth | 19.8 |
| Gross Profit (p.s.) | |
| Sales Per Share | 52.601 |
| EBITDA (p.s.) | 22.821 |
| Qtrly Earnings Growth | -52.40 |
| Operating Cash Flow (M) | 8470.00 |
| Levered Free Cash Flow (M) | 3120.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 21.16 |
| PEG Ratio | 2.70 |
| Price to Book value | 22.69 |
| Price to Sales | 5.02 |
| Price to Cash Flow | 16.71 |
| Stock Dividends | |
|---|---|
| Dividend | 2.250 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
